Yearly Archive

Yearly Archives: 2014

August 19, 2014 no comments

After NICE is it time for NASTY? National Academy for the Study of Things that harm You

The United Kingdom’s National Institute for Clinical Excellence (NICE) has proven its worth as an independent arbiter of value-for-money when it comes to medical interventions.  People may question the details of the methodology they employ to compare effectiveness of drugs and procedures, but few doubt the principle of its existence.

Unfortunately, there is no equivalent framework for assessing public health interventions.  A swathe of unreliable cross0-secvtional studies have highlighted potential harms from a diverse array of sources, but particularly various components of our diet.  A vocal minority is calling for action to limit these perceived “harms”.  But how real is the risk?  Even where the risk is proven, how much of a contributor to our overall health are these factors? There is a very real risk governments will start to intervene (through legislation or tax measures to disincentives certain behaviours) on the basis of public perception rather than a quantitive, rational and transparent assessment of the costs and benefits of such interventions.

The solution, according to DrugBaron, is to adopt the NICE methodology to estimate value-for-money of proposed public health interventions, in exactly the same way we do for medical interventions.  This would be the mission of the National Academy for the Study of Things that harm You (NASTY).

More

More
April 30, 2014 no comments

Drug prices are (unnecessarily) high because R&D is (unnecessarily) inefficient

Let me put it in bold text and …

More
April 15, 2014 comments

What Thomas Dimsdale, arguably the world’s first biotech entrepreneur, tells us about drug pricing

Thomas Dimsdale (born in 1712) was arguably the …

More
March 3, 2014 no comments

Medicalizing biomarkers – the sure-fire road to commercial success

Creating new drugs is a process fraught with …

More
October 16, 2013 no comments

Clinical trial transparency: time for some carrot as well as more stick?

Today, the majority of clinical trials that are …

More
June 4, 2013 no comments

Better drugs cannot cure healthcare system woes

For those of us investing money or our …

More
January 29, 2013 comments

The REAL scandal of drug pricing

Healthcare provision, at least in the Western world, …

More
December 4, 2012 comments

What price an orphan this Christmas?

Tiny Tim wasn't the only orphan to suffer …

More

Yearly Archive